Department of Radiation Oncology, National Cancer Centre, Singapore.
Gynecol Oncol. 2011 Nov;123(2):225-9. doi: 10.1016/j.ygyno.2011.06.040. Epub 2011 Jul 23.
The use of adjuvant radiotherapy for early stage node negative patients varies for different institutions. The recognized factors such as deep stromal invasion, lymph vascular space invasion, and size of tumor are the most common factors cited for adjuvant radiotherapy. Studies done have shown that this increases local control but may increase chronic toxicity rates. We report on our use of the GOG score to tailor our treatment decisions.
A review of all patients staged IB-IIA who underwent Type 3 Radical Hysterectomy and pelvic lymph node dissection (RH) from 1997 to 2007. The GOG score proposed by Delgado et al. was applied, and patients were stratified into 3 groups; <40: no adjuvant treatment, 40-120: Small Field RT (SmRT), and >120: Standard Field RT (StRT) RESULTS: A total of 126 patients matched these criteria. Sixty one patients underwent either SmRT or StRT. There were only 2 known relapses and one death due to inter current illness. The median follow up was 57 months and the 5 year Disease Free Survival was 98.2%. There were no documented Grade 3 or 4 chronic toxicities. There were significantly less (p=0.025) patients with lower limb lymphedema in the SmRT group compared to StRT.
Our study confirms the utility of the GOG score to tailor radiotherapy for this cohort of patients. This has been proven to be high in efficacy and low in morbidity.
对于早期淋巴结阴性患者,辅助放疗的使用因机构而异。公认的因素如深层间质浸润、淋巴管血管间隙浸润和肿瘤大小是最常被引用的辅助放疗因素。研究表明,这可以提高局部控制率,但可能会增加慢性毒性发生率。我们报告了我们使用 GOG 评分来制定治疗决策的情况。
回顾 1997 年至 2007 年间接受 3 型根治性子宫切除术和盆腔淋巴结清扫术(RH)的所有 IB-IIA 期患者。应用 Delgado 等人提出的 GOG 评分,将患者分为 3 组;<40:无辅助治疗,40-120:小野放疗(SmRT),>120:标准野放疗(StRT)。
共有 126 名符合这些标准的患者。61 名患者接受了 SmRT 或 StRT。仅发生 2 例已知复发和 1 例因并发疾病死亡。中位随访时间为 57 个月,5 年无病生存率为 98.2%。无记录的 3 级或 4 级慢性毒性。SmRT 组下肢淋巴水肿的患者明显较少(p=0.025)。
我们的研究证实了 GOG 评分在制定这组患者放疗方案中的效用。这已被证明在疗效上高,在发病率上低。